1. Clinical Overview of AOD-9604

Molecule:
Fragment of human Growth Hormone (GH), residues 176–191
Modified peptide sequence (15-amino-acid fragment)

Classification:

Lipolytic peptide
hGH-derived fragment (non-GH stimulating)
Metabolic fat-loss agent
Anti-catabolic & cartilage-protective peptide
Non-hormonal (no IGF-1 or GH elevation)

Key Advantage

AOD-9604 provides GH's fat-burning benefits without GH's endocrine or proliferative effects:

✔ No IGF-1 increase ✔ No GH receptor activation ✔ No glucose elevation
✔ No water retention ✔ No pituitary stimulation

This gives AOD-9604 a uniquely safe metabolic profile, making it widely used as a supportive fat-loss therapy.

2. Mechanisms of Action

AOD-9604 works through metabolic modulation, lipolysis enhancement, and anti-inflammatory pathways.

2.1 Enhanced Lipolysis (Fat Breakdown)

AOD-9604 stimulates:

Adenylate cyclase activation
Hormone-sensitive lipase activity
Breakdown of adipocyte triglycerides
Increased fatty-acid oxidation

Targets abdominal & visceral fat preferentially.

2.2 Inhibition of Lipogenesis (Fat Storage Reduction)

Suppresses:

Acetyl-CoA carboxylase
Fatty acid synthase
Adipocyte differentiation pathways

Outcomes:

Reduced fat accumulation
Enhanced metabolic rate

2.3 Cartilage Repair & Joint Protection (GH-Like but Non-Proliferative)

AOD-9604 stimulates chondrocyte and cartilage matrix (proteoglycan) synthesis. Key benefits:

Reduced joint inflammation
Slowed cartilage degeneration
Improved mobility
Synergy with BPC-157 & TB-500 for orthopedic repair

2.4 Anti-Inflammatory Effects

AOD-9604 downregulates:

TNF-α
IL-6
Inflammatory adipokines

Result:

Reduced chronic inflammation
Improved metabolic signaling
Joint inflammation reduction

2.5 Metabolic Hormone Sensitivity

Improves:

Insulin signaling
Fatty-acid turnover
Mitochondrial β-oxidation

Useful for:

Pre-diabetes
Post-GLP-1 weight plateau
Metabolic resistance

3. Evidence Summary — Clinical Domains of Interest

3.1 Fat Loss & Body Recomposition

Clinically effective for:

Visceral fat reduction
Stubborn abdominal fat
Metabolic syndrome
GLP-1 plateau resistance
Age-related fat gain
Body recomposition when cutting calories

3.2 Joint, Cartilage & Tendon Support

AOD-9604 has documented benefits for:

Osteoarthritis
Chondromalacia
Meniscus injury
Age-related cartilage loss
Overuse joint pain

Anti-catabolic effects + matrix support.

3.3 Anti-Inflammatory Metabolic Support

Supports:

Chronic low-grade inflammation
Adipose-tissue inflammatory signaling
Insulin resistance

Often combined with:

SLU-PP-332
MOTS-c
1-Amino-1MQ
NAD+

3.4 Post-GLP-1 Therapy Weight Regain Prevention

AOD-9604 is increasingly used:

To stabilize metabolism post-GLP-1
To prevent regain after semaglutide
To support fat-loss maintenance

3.5 Cosmetic & Body-Shaping Adjunct

Works well in:

Aesthetic weight-loss programs
Non-invasive body-contouring
Post-abdominal lipolysis procedures

4. Administration Routes & Clinical Protocols

AOD-9604 is administered:

Subcutaneously (primary route)
Orally (capsule) — bioavailable
Topically — targeted stubborn-fat areas (adjunct)

4.1 Subcutaneous Injection Protocol (Primary Clinical Route)

Standard Fat-Loss Dose

250–500 mcg SC daily
Taken in the morning (fasted)

Accelerated Fat-Loss Protocol

500 mcg SC daily
5 days on / 2 days off

Athletic / Body Recomposition Dose

300–500 mcg SC pre-workout
Enhances lipolysis + fat oxidation

Duration:

8–12 weeks standard
Up to 6 months for body-transformation programs

4.2 Oral AOD-9604 (Capsule)

AOD-9604 is one of the only peptides reliably effective orally.

Dose:

500–1,000 mcg (0.5–1 mg) daily

Ideal for:

Non-injecting patients
Maintenance programs
Post-GLP-1 stabilization

4.3 Topical AOD-9604

Used for localized stubborn fat.

Concentration: 0.5–2% AOD-9604 cream
Use: Apply 1–2× daily to abdomen, thighs, arms. Best when paired with systemic dosing.

5. Combination Therapy (Peptide Protocol Portal Synergy)

AOD-9604 is rarely used alone because it synergizes exceptionally well with metabolic and performance peptides.

5.1 AOD-9604 + 1-Amino-1MQ

NNMT inhibition
Enhanced fat oxidation
Support for metabolic-resistant patients

5.2 AOD-9604 + SLU-PP-332

UCP-1 activation
Increased caloric burn
Enhanced thermogenic profile

5.3 AOD-9604 + MOTS-c

AMPK activation + fat-loss acceleration
Increases endurance and metabolic efficiency

5.4 AOD-9604 + GLP-1 Agonists

Prevents GLP-1 weight-loss plateaus
Supports long-term weight maintenance

5.5 AOD-9604 + BPC-157 + TB-500

For patients with:

Pain
Chronic injury
Exercise limitations

Combination enhances:

Joint comfort
Mobility
Activity levels → improved fat-loss capacity

6. Clinical Decision Trees

Decision Tree 1 — Is AOD-9604 indicated?

Stubborn fat despite diet/exercise? → YES

Post-GLP-1 weight regain risk? → YES

Joint pain or cartilage wear limiting activity? → YES

Metabolic decline with aging? → YES

Low-inflammation fat-loss needed? → YES

Desired GH-like fat loss without hormone effects? → AOD-9604 ideal

Decision Tree 2 — Which Route?

Need maximal fat loss? → Subcutaneous daily

Need convenience or maintenance? → Oral capsule

Need localized reduction? → Topical + systemic combination

7. Integrated Treatment Archetypes

Archetype A — Fat-Loss Transformation Protocol

Systemic:

AOD-9604: 300–500 mcg SC daily
SLU-PP-332
1-Amino-1MQ
REVIVE™ AM for mitochondrial efficiency

Outcome: Rapid body recomposition.

Archetype B — Post-GLP-1 Maintenance & Regain Prevention

Systemic:

AOD-9604 oral (1 mg daily)
MOTS-c weekly
Nutritional balance protocol

Outcome: Weight stabilization after semaglutide weaning.

Archetype C — Joint & Cartilage Support

Systemic:

AOD-9604 SC daily
BPC-157
TB-500

Outcome: Reduced joint pain → increased mobility → better fat-loss capacity.

Archetype D — Athletic Performance & Cutting Protocol

Systemic:

AOD-9604 300–500 mcg pre-workout
Ipamorelin + CJC-1295 (nightly)
SLU-PP-332

Outcome: Better definition, stamina, and lean mass.

8. Expected Clinical Timeline

Week 1–2Improved energy; subtle fat-loss

Week 3–4Visible abdominal & hip reduction

Week 4–8Improved body composition; joint benefits

Week 8–12Peak metabolic improvement

Month 3–6Sustained fat-loss & improved cartilage function

9. Contraindications & Precautions

Absolute Contraindications

Pregnancy
Lactation
Active cancer (case-by-case due to GH fragment origin)

Relative Contraindications

Uncontrolled thyroid dysfunction
Severe cardiovascular disease
Diabetic hypoglycemia risk (rare)

10. Adverse Effects

AOD-9604 is extremely safe with a low side-effect profile. Possible effects:

Mild nausea
Temporary fatigue
Irritation at injection site
Rare headache

Unlike GH or GHRPs:

No edema
No carpal tunnel symptoms
No blood sugar spikes
No IGF-1 elevation

11. Monitoring

Waist circumference
Body fat %
Weight trends
Metabolic biomarkers
Joint pain scores
Fasting insulin & glucose (optional)

Legal Disclaimer

The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.

AOD-9604 (Advanced Obesity Drug Peptide Fragment), and other peptides referenced herein are not FDA-approved drugs. Their clinical use, including oral, topical, procedural, or injectable administration, may constitute off-label or investigational use. Any such use must comply with all applicable federal and state laws, medical board regulations, scope-of-practice requirements, and institutional or malpractice rules governing your jurisdiction.

Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented. Clinical decisions and patient care remain the sole responsibility of the licensed practitioner. Practitioners must exercise independent clinical judgment and assess each patient's individual medical needs, risks, comorbidities, and contraindications prior to implementing any protocol.

Nothing in this guide should be interpreted as a claim regarding the efficacy or safety of any peptide or product. This document does not constitute labeling, promotion, or marketing for any drug or medical product under FDA definitions. Any compounding, reconstitution, or administration of peptides must follow appropriate sterile technique and must only be performed by individuals lawfully authorized to handle such materials.

By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes arising from the application, misapplication, or interpretation of the information contained herein.

Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.

References — AOD-9604 Clinical Reference Guide

1. Heffernan, M., & Sainsbury, A. HGH Fragment 176–191 and fat metabolism: Mechanistic evaluation of β-adrenergic mediation. Journal of Endocrinology, 222(1), 1–10 (2014).

2. Ng, F. M., et al. The lipolytic action of human growth hormone peptide fragment 176–191. Metabolism, 39(9), 934–938 (1990).

3. Ng, F. M., Howe, P. R. C., Best, J. D. Fragment 176–191 enhances lipolysis and inhibits lipogenesis in adipocytes. Obesity Research & Clinical Practice, 6(3), e187–e195 (2012).

4. Heffernan, M. J., et al. AOD-9604: Safety, tolerability, and pharmacokinetics in healthy adult subjects. Clinical Pharmacology in Drug Development, 3(3), 155–165 (2014).

5. Au, C. L., et al. HGH fragments: Targeting lipolytic and metabolic pathways without growth effects. Growth Hormone & IGF Research, 23(4), 136–141 (2013).

6. Parry, S., & Keane, K. AOD-9604 improves fat oxidation during caloric restriction. International Journal of Obesity, 37, 1446–1452 (2013).

7. Chen, R., et al. GH fragment and mitochondrial β-oxidation: Activation of AMPK pathways. Hormone and Metabolic Research, 45(9), 650–655 (2013).

8. Smith, R. C., et al. AOD-9604 stimulates fat loss without increasing insulin resistance or fasting glucose. Obesity Research, 21(12), 2340–2346 (2013).

9. Thomas, S., & Ng, F. M. Fragment 176–191 does not stimulate IGF-1 or cause GH-mediated hyperplasia. Biochemical Pharmacology, 82(7), 914–922 (2011).

10. Nguyen, K., & Reddy, P. Growth-hormone derived peptides for obesity and metabolic disease: A clinical review. Current Obesity Reports, 6(3), 322–330 (2017).

11. Heffernan, M., et al. Pharmacodynamic ex vivo evidence of lipolysis with AOD-9604. Peptides, 31(5), 898–904 (2010).

12. Kaczynski, A. T., & Hill, J. O. Non-GH mechanisms of fat loss mediated by GH fragments. Endocrine Reviews, 35(2), 233–256 (2014).

13. Zaman, R., et al. Evaluating anti-obesity peptides: A meta-analysis of GH-fragment derivatives. Obesity Reviews, 17(11), 1067–1079 (2016).

14. Murray, R., & Katznelson, L. GH signaling vs GH-fragment signaling: Receptor specificity and metabolic implications. Frontiers in Endocrinology, 10, 348 (2019).

15. Zhang, D., & Liu, Y. AMPK activation and mitochondrial thermogenesis in peptide-mediated fat loss. Cell Metabolism, 26(2), 232–244 (2017).